Client news

A&O Shearman supports GSK on its antibody conjugate cancer therapy license agreement with HUTCHMED

A&O Shearman supports GSK on its antibody conjugate cancer therapy license agreement with HUTCHMED
Published Date
Sep 4, 2026
Related people
Image of Jim Ford
Jim FordPartner, London
Image of Megan McMellon
Megan McMellonSenior Associate, London
Image of Millie Fantham
Millie FanthamAssociate, London
A&O Shearman has advised global biopharma GSK on its licensing agreement with HUTCHMED, under which HUTCHMED will exclusively license to GSK on a worldwide basis (excluding mainland China, Hong Kong, Macau, and Taiwan) HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate (ATTC).

HMPL-A830 is expected to enter clinical trials in H2 2026, with clinical development initially focusing on colorectal, pancreatic, and lung cancer indications.

The A&O Shearman team was led by IP transactions partner Jim Ford and IP transactions senior associate Megan McMellon, supported by IP transactions associate Millie Fantham. Jonathan Cheng, Elaine Johnston, Regina Loureiro, and Andrew Shaeffer also provided antitrust support. 

“It was a pleasure to advise GSK on another significant licensing transaction.”

Related capabilities